Impulse control disorders in parkinson’s disease
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
There is an increasing awareness that impulse control disorders (ICDs), including pathologic gambling and compulsive sexual behavior, can occur as a complication of Parkinson’s disease (PD). Anecdotal experience and case reporting have suggested an association between ICDs in PD and the use of dopamine agonists. Lacking established treatments for ICDs in PD, clinical management should initially consist of modifications to or discontinuation of dopamine replacement therapy, particularly dopamine agonists. It is important that PD patients be aware that dopamine agonist use may lead to the development of an ICD, and that clinicians monitor patients as part of routine clinical care. As empirically validated treatments for ICDs are emerging, it will be important to examine their efficacy and tolerability in individuals with co-occurring PD and ICDs.
- American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000. CrossRef
- Grant JE, Levine L, Kim D, Potenza MN: Impulse control disorders in adult psychiatric inpatients. Am J Psychiatry 2005, 162:2184–2188. CrossRef
- Potenza MN, Hollander E: Pathological gambling and impulse control disorders. In Neuropsychopharmacology: The 5th Generation of Progress. Edited by Coyle JT, Nemeroff CB, Charney DS, Davis KL. Baltimore, MD: Lippincott Williams & Wilkins; 2002:1725–1742.
- Potenza MN, Kosten TR, Rounsaville BJ: Pathological gambling. JAMA 2001, 286:141–144. CrossRef
- Black DW, Kehrberg LL, Flumerfelt DL, et al.: Characteristics of 36 subjects reporting compulsive sexual behavior. Am J Psychiatry 1997, 154:243–249.
- Black DW, Repertinger S, Gaffney GR, et al.: Family history and psychiatric comorbidity in persons with compulsive buying. Am J Psychiatry 1998, 155:960–963.
- Molina JA, Sáinz-Artiga MJ, Fraile A, et al.: Pathologic gambling in Parkinson’s disease: a behavioral manifestation of pharmacologic treatment? Mov Disord 2000, 15:869–872. CrossRef
- Gschwandtner U, Aston J, Renaud S, et al.: Pathological gambling in patients with Parkinson’s disease. Clin Neuropharmacol 2001, 24:170–172. CrossRef
- Seedat S, Kesler S, Niehaus DJ, et al.: Pathological gambling behaviour: emergence secondary to treatment of Parkinson’s disease with dopaminergic agents. Depress Anxiety 2000, 11:185–186. CrossRef
- Driver-Dunckley E, Samanta J, Stacy M: Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease. Neurology 2003, 61:422–423. The first large-scale retrospective chart review to report on the frequency and characteristics of pathologic gambling in PD, including its possible association with dopamine agonist treatment.
- Dodd ML, Klos KJ, Bower JH, et al.: Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005, 62:1–5. Recent case series in PD that used formal diagnostic criteria for pathologic gambling and also suggested an association between dopamine agonist treatment, particularly pramipexole, and pathologic gambling in this population. CrossRef
- Klos KJ, Bower JH, Josephs KA, et al.: Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson’s disease and multiple system atrophy. Parkinsonism Related Disord 2005, 11:381–386. Recent case series reporting on the occurrence of compulsive sexual behavior in PD and its possible association with dopamine agonist treatment, suggesting that dopamine agonist treatment may be associated with the development of ICDs other than pathologic gambling in PD. CrossRef
- Evans AH, Katzenschlager R, Paviour D, et al.: Punding in Parkinson’s disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004, 19:397–405. CrossRef
- Giovannoni G, O’Sullivan JD, Turner K, et al.: Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000, 68:423–428. CrossRef
- Pezzella FR, Di Rezze S, Chianese M, et al.: Hedonistic homeostatic dysregulation in Parkinson’s disease: a short screening questionnaire. Neurol Sci 2003, 24:205–206. CrossRef
- Serrano-Dueñas M: Chronic dopamimetic drug addiction and pathologic gambling in patients with Parkinson’s disease—presentation of four cases. German J Psyhiatry 2002, 5:62–66.
- Voon V: Repetition, repetition, and repetition: compulsive and punding behaviors in Parkinson’s disease. Mov Disord 2004, 19:367–370. CrossRef
- Evans AH, Lawrence AD, Potts J, et al.: Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005, 65:1570–1574. CrossRef
- Kurlan R: Disabling repetitive behaviors in Parkinson’s disease. Mov Disord 2004, 19:433–437. CrossRef
- Hollander E, Evers M: New developments in impulsivity. Lancet 2001, 358:949–950. CrossRef
- Potenza MN, Leung HC, Blumberg HP, et al.: An fMRI Stroop task study in ventromedial prefrontal cortical function in pathological gamblers. Am J Psychiatry 2003, 160:1990–1994. This study reported decreased activity on functional MRI in the ventromedial prefrontal cortex in non-PD pathologic gamblers relative to comparison subjects when completing the Stroop paradigm, a task of response inhibition that is thought to reflect impulse control abilities. CrossRef
- Bechara A, Tranel D, Damasio H: Characterization of the decision-making deficit of patients with ventromedial prefrontal cortex lesions. Brain 2000, 123:2189–2202. CrossRef
- Reuter J, Raedler T, Rose M: Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 2005, 8:147–148. This study reported reduced ventral striatal (ie, the nucleus accumbens) and ventromedial prefrontal cortex activation on functional MRI in non-PD pathologic gamblers compared with control subjects when performing a simulated gambling task. In the subjects who suffered from pathologic gambling, activation of both regions was inversely correlated with gambling severity (ie, lower activation correlated with increased gambling severity). CrossRef
- Bechara A, Damasio H, Damasio AR, Lee GP: Different contributions of the human amygdala and ventromedial prefrontal cortex to decision-making. J Neurosci 1999, 19:5473–5481.
- Chambers R A, Potenza MN: Neurodevelopment, impulsivity, and adolescent gambling. J Gambling Studies 2003, 19:53–84. CrossRef
- Bjarkam CR, Sørensen JC: Therapeutic strategies for neurodegenerative disorders: emerging clues from Parkinson’s disease. Biol Psychiatry 2004, 56:213–216. CrossRef
- Levin BE, Katzen HL: Early cognitive changes and nondementing behavioral abnormalities in Parkinson’s disease. In Behavioral Neurology of Movement Disorders. Edited by Weiner WJ, Lang AE. New York: Raven Press; 1995:85–95.
- Green J, McDonald WM, Vitek JL, et al.: Cognitive impairments in advanced PD without dementia. Neurology 2002, 59:1320–1324.
- Fuster JM: Frontal lobe syndromes. In Neuropsychiatry. Edited by Fogel BS, Schiffer RB, Rao SM. Baltimore: Williams & Wilkins; 1996:407–413.
- Dubois B, Pillon B: Cognitive deficits in Parkinson’s disease. J Neurol 1997, 244:2–8. CrossRef
- Brand M, Labudda K, Kalbe E, et al.: Decision-making impairments in patients with Parkinson’s disease. Behav Neurol 2004, 15:77–85.
- Gerlach M, Double K, Arzberger T, et al.: Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm 2003, 110:1119–1127. CrossRef
- Sokoloff P, Giros B, Martres MP, et al.: Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990, 347:146–151. CrossRef
- Tyne HL, Medley G, Ghadiali E, Steigner MJ: Gambling in Parkinson’s disease. Mov Disord 2004, 19(Suppl 9):S195.
- Olanow CW, Watts RL, Koller WC: An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology 2001, 56(Suppl 5):S1-S88.
- Lesieur HR, Blume SB: Revising the South Oaks Gambling Screen in different settings. J Gambling Studies 1993, 9:213–223. CrossRef
- Potenza MN, Fiellin DA, Heninger GR, et al.: Gambling: an addictive behavior with health and primary care implications. J Gen Intern Med 2002, 17:721–732. CrossRef
- Grant JE, Potenza MN: Impulse control disorders: clinical characteristics and pharmacological management. Ann Clin Psychiatry 2004, 16:27–34.
- Grant JE, Potenza MN, Hollander E, et al.: Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 2006, 163:303–312. Recent double-blind, placebo-controlled study in pathologic gamblers without PD. The opioid antagonist nalmefene, particularly when dosed at 25 mg/d, was superior to placebo in reducing gambling-related thoughts and behaviors and decreasing patientreported disability. This study represents the largest treatment trial involving subjects with pathologic gambling that has been published to date, and supports the drug’s use in the short-term treatment of pathologic gambling. CrossRef
- Hodgins DC, Petry NM: Cognitive and behavioral treatments. In Pathological Gambling: A Clinical Guide to Treatment. Edited by Grant JE, Potenza MN. Washington DC: American Psychiatric Press; 2004:169–188.
- Impulse control disorders in parkinson’s disease
Current Neurology and Neuroscience Reports
Volume 6, Issue 4 , pp 302-306
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links